Rejuvenate Bio Raises $6M in Funding Round Led by VCapital

The round also saw participation from Merck Animal Health, Kendall Capital Partners, Connecticut Innovations, and Digitalis.

The company plans to use the funding to continue developing its platform and product pipeline, including new treatments for chronic and age-related diseases in companion animals such as dogs and cats.

Rejuvenate Bio is developing gene therapies designed to improve health, extend lifespan, and treat chronic diseases. Its platform uses advances in gene delivery, biology, and longevity research to create treatments for companion animals, with the long-term goal of applying the technology to human health.

The partnership with Merck Animal Health will focus on developing a targeted gene therapy program using Rejuvenate Bios technology platform, and expertise in translating research into practical treatments.

“We believe gene therapy has the potential to transform the treatment of chronic disease, and age related conditions fundamentally,” said Daniel Oliver, CEO & Co-Founder, Rejuvenate Bio. “This financing and strategic collaboration with Merck Animal Health validates both the strength of our platform, and the growing interest in innovative approaches to animal health. We are excited to work alongside leading investors and industry partners to accelerate the development of transformative therapies for veterinary medicine.”

Read More:PointFive Raises $60M in Series B Funding Led by Accel

“This investment reflects our ongoing commitment to partner with leading innovators to advance new capabilities in animal health,” said Jim McIntyre, head of business development, Merck Animal Health. “We are eager to partner with Rejuvenate Bio to explore potentially transformative technologies and therapeutics to market that address important unmet needs in veterinary medicine.”

About Rejuvenate Bio

Founded in 2019 by George Church, Daniel Oliver, Noah Davidsohn, and Deborah Ascheim, Rejuvenate Bio is a biotechnology company focused on developing gene therapies for chronic age-related diseases. The company is building a pipeline of treatments based on clinically validated gene targets and a delivery approach designed to provide long-lasting and well-tolerated results.

Read More:Edge Markets Raises $29.2M in Series A Funding Led by CoinFund